A Phase I/II, Open-Label, Multicenter Study of ALE.P02 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients with Selected Advanced or Metastatic CLDN1+ Squamous Solid Tumors Read more
A Phase I/II, Open-label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-drug Conjugate) as a Monotherapy in Adult Patients with Selected Advanced or Metastatic CLDN1+ Solid Tumors Read more
Real World Outcomes with Amivantamab Monotherapy in Patients with non-Exon 20 Insertion Epidermal Growth Factor Receptor (EGFR)-mutated Non-small Cell Lung Cancer (NSCLC) Read more
A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients with Selected Advanced Solid Tumors Read more
An Investigational Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors Read more
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors Read more
Phase Ia, first in human open label, dose escalation trial evaluating intravenous BI 1703880 in combination with intravenous ezabenlimab for treatment of advanced solid tumours Read more
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Tumors Read more
A PHASE I/II STUDY OF AKR1C3-ACTIVATED PRODRUG OBI8208;3424 (OBI-3424) IN PATIENTS WITH RELAPSED/REFRACTORY TCELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) / T-CELL LYMPHOBLASTIC LYMPHOMA (T-LBL) Read more
